Vanguard Group Inc. boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,904,340 shares of the life sciences company’s stock after purchasing an additional 255,498 shares during the period. Vanguard Group Inc. owned about 6.78% of Illumina worth $1,718,601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Paradigm Asset Management Co. LLC lifted its position in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 50 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its position in Illumina by 1.4% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock valued at $528,000 after purchasing an additional 43 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in Illumina by 298.7% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock valued at $1,813,000 after purchasing an additional 7,827 shares during the period. Eagle Asset Management Inc. acquired a new position in Illumina during the second quarter valued at $27,175,000. Finally, Stephens Investment Management Group LLC lifted its position in Illumina by 0.5% during the second quarter. Stephens Investment Management Group LLC now owns 168,706 shares of the life sciences company’s stock valued at $29,274,000 after purchasing an additional 803 shares during the period. Institutional investors own 93.32% of the company’s stock.

In other Illumina news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $174.24, for a total transaction of $25,264.80. Following the completion of the transaction, the senior vice president now owns 10,646 shares in the company, valued at $1,854,959.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $172.92, for a total transaction of $2,593,800.00. Following the transaction, the director now owns 534,176 shares of the company’s stock, valued at approximately $92,369,713.92. The disclosure for this sale can be found here. Insiders sold 175,188 shares of company stock valued at $33,870,937 in the last quarter. Company insiders own 1.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Vanguard Group Inc. Boosts Position in Illumina, Inc. (ILMN)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/vanguard-group-inc-boosts-position-in-illumina-inc-ilmn/1582388.html.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at 201.41 on Friday. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $214.34. The company’s 50-day moving average is $199.76 and its 200 day moving average is $181.17. The stock has a market cap of $29.41 billion, a PE ratio of 40.41 and a beta of 0.81.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662.00 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter last year, the business earned $0.86 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on ILMN shares. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a research report on Wednesday, May 31st. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Morgan Stanley restated an “underweight” rating and set a $122.00 target price (up from $115.00) on shares of Illumina in a research report on Monday, July 10th. Barclays PLC restated a “hold” rating and set a $150.00 target price on shares of Illumina in a research report on Wednesday, July 19th. Finally, Canaccord Genuity restated a “hold” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $182.15.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.